RayVa is in a proof of concept study (it is a cream) for acute secondary Raynaud's Phenomenon which is a rare disorder with characteristis of stiff, cold swelled up fingers. Blood vessels are narrowed and thus it is thought that increasing blood flow could aid as RayVa should do...just as Apri's ED drug.
With this being a rare disease...if this drug would work Apricus could basically name their price and then test it on other diseases as possible secondary treatments for Lupus or other autoimmune diseases.
Enrollment of the final patient in this Phase II-A has been enrolled and results are expected in 3rd quarter....hopefully by September, but this really could be a nice Catalyst for this company and I expect a nice run up into the release of data.
They also have a couple approved drugs and they are currently expanding their ED drug in European countries and just made a deal with Spain which has about a $200 million dollar market itself and once this is prescribed I believe it will catch on as it is a cream and there are some people that would rather experiment with Creams vs Viagra and there are those that will go for the Gusto...do a bit of doctor shop and use both to really get a nice #$%$.
This company has established multiple partners and their future looks bright.
Now looking at the Chart: I usually don't invest in companies before I take a long look at the chart. I will start with the Weekly Chart and move backwards. I really expect this stock to hit $2.30 --- to $2.75 according to the weekly chart. There was a Major Buy Signal on the Weekly Chart 3 weeks ago around 1.65 and it has only moved 20 cents since this time. No let's go to the Daily Chart: A major buy signal was around 1.70, just a couple trading days ago. Now the price being 2.87, that is only .17 cents. Watch for a little more volume to see if we can break above $2.00 which would be a great sign that this is going MUCH higher.
Bottom Line: I like the chart right now. Cont
I remember you well bud.
CTIX --- it won't move until shareholders see ACTUAL DATA.
This ---just has all the makings of something very special.
You did very well in HZNP if you've held for that long.
AVXL --- It's going to be BIG
I have a lot of orders to buy tomorrow at a range of prices and will buy on all dips from now on.
Sentiment: Strong Buy
Excellent point and Very True.
Esque1954: Taking from CTIX and giving to this will be MUCH more rewarding.
Prospern23: Yeah, now is time to buy.
I did also.
I tried buying TPIV at .50 and was going to go all in, the second I put that order in the ask went up and the bid followed it. That was one time it was Worth Chasing, but I was too proud and didn't do it...20/20 hindsight says I could of more than tripled and I thought .50 cents was too high....NOT this time. This could be another, but I only unloaded a tenth of what I had so it's not a huge deal.
This is going much higher. I was foolish and took a little off the table in attempt to buy back a few pennies cheaper, now I may have to chase this.
As mentioned previously but worth repeating and repeating....computational simulated models indicates at least 2 x Boost Response with Anavex Plus vs aricept alone. That would be quite a response.
Even if all the drugs in development end up working...this will be a Multi-Billion dollar company and would be bought out much before that level.
You don't think that companies like Pfizer or Biogen are not aware of little Anavex...Oh, No, they are watching and waiting diligently. They usually don't make moves until two efficacy trials have been confirmed, but AD is worth an extra risk of purchasing.
This could end up being a Multi-Billion Dollar company and Pfizer could buy this for pennies on the dollar even at $10 bucks.
That Monsanto article may have brought buyers to SYN.
You may see a filing but as far as partnership...I doubt it.
Dr. V may be waiting until the end of the year for the end of Cog study?
Something just doesn't sound right about her not wanting to disclose data and if you have good news, you want to get that out as soon as possible. Makes me wonder.
The cash situation isn't necessarily great, so Riley better be sticking to his promises about non-dilutive funding...he has been saying this for six months now on Pertussis.
He speaks of partnering regarding the IBS drug also.
Cash has to be getting at a Worrisome level.
Selfishly I was hoping for it to dip to .40 prior to taking off. This should be a nice Long Term hold and there will be a LOT of Distribution along the way up, but eventually the smart money will buy in and they will Hold and not even think about selling.
$7.00 price target and they have one heck of a platform.
Undervalued at $5.00 a share and am surprised it's taken this long to receive any attention.
Looking at the Weekly Chart there may be some resistance around .60 cents, but after it busts through that it should sail away to .85 and Beyond!
I'm just telling what this overhang will cause.
I bought in at around 3.90-$4.01 and sold for a nice profit. Now I believe it is going much lower over the next few weeks or more.
with the outstanding shares, 423.1 Million, then you have Options and Warrants.
The market cap is actually $73.2 Million USD, but all the warrants and options will equal a lot of shares of dilution in the future, which will keep pressure on this stock.
Now I expect a "dead" period for a while. Meaning some consolidation and a slow drift down, beginning in about a week from now.
As far as product and potential...it's great, but we have to now put up with all the recent Freebies that GK just GAVE for investing, which that can NEVER be negotiated like this EVER Again.
It is not good for the stock when you have an over hang of a ton of options and warrants. I imagine he did what he had to do to get funding, and he dang well knew that it would cut the stock by at the very least 50%.
These are the growing pains of a tiny company.
Could be a Red Day tomorrow for everyone. Tomorrow wouldn't be the best time to release news as it likely wouldn't be maximized.
Greece and now Puerto Rico in trouble.
Italy is near behind...not looking great on a global level.
Shorts go by average of success or failure and unfortunately most have failed, but they are now coming closer to finding drugs that can improve cognitive functioning and providing neuroprotection to slow or even halt the degeneration.
RE: Alz Story --- my 7th grade Science Teacher was diagnosed with Alzheimer's when he was about 44 --- he had a very rapid degenerating form of AD and was in nursing home in 3 1/2 years and was gone within 5 years. It shocked about everyone in our small town as this man was very well respected, intelligent, active, a coach, a great father but yet even he wasn't susceptible to this disease in which we still do not know the cause.
If 73-plus can prove to be twice effective than Aricept, then this will be a winner...regardless of any other drugs approved.
If any success, this company will be bought out...probably by Pfizer as they were familiar with Aricept and know the revenues. There is NO way that a big fish will allow a minnow fry like Anavex to partner if results stellar --- they will want to own them and with a market cap of less than $100 million and revenues that would likely be in the Multi-Billions on a yearly basis...think about it; if AVXL comes out with compelling data this could immediately change this tiny penny company overnight.
Thinking a bit more positively on the combination of 73 and Aricept...AVXL indicates this works synergistic with Aricept and has neuroprotecitve and memory improvements that were statistically significant with the mouse models...YES, I know it's a dang mouse. That is why ANY positive news relative to human which correlates with preclinical work would be very Significant news. Memory improvement was up to 80% in animal models.
Also awaiting a patent on on the Combination if granted would allow exclusive protection until 2033.
AVXL performed a computational simulated model in which it forecasts Anavax Plus works twice as good vs Aricept alone. There are some complex mathematical equations to compute with these simulations, but they may prove to be an important tool to analyzing drug effects on AD.
AVXL mentions that 2-73 could be beneficial in treating Epilepsy and they say that 3-71indicates therapeutic advantages in AD and Aggregation Related Diseases. I wonder is they have brainstormed about a possible study with Systemic Amyloidoses? That is a major potential as well.
This company may be on to something. They can also study their own platform drugs in combination...all they need to do is get the word out and increase interest from larger companies.
I totally realize that this company is extremely Young relative to Clinical Studies. This company just needs time, some positive clinical data to spread around and eventually a good partner for one of their several platforms.
By 2025 the projected expenses for Alzheimer's Disease will be WELL Over $100 Billion dollars and this would/could/should be the Prime of AVXL's Alzheimer's drugs.
I don't usually invest in OTC companies but I did in CTIX at a Very EARLY stage...earlier than this one and it paid off big time. I believe that this company has equal potential in the CNS and Cancer fields.
This is just a baby attempting to stand on its own two feet!
The only thing your mastering is your stupidity. Who is "We"...you and your imaginary friends.
"Based on Research" I think you or whomever you are bashing for wants some cheaper shares.
I've read some of your posts and they are beyond the profound #$%$ category.
The only Short you have is in your pants that's why your imaginary friend calls you stubby.